|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here, we investigate a unique variant of familial hypercalcemia, unrelated to multiple endocrine neoplasia and hyperparathyroidism-jaw tumor syndromes, with hypercalcemia due to a point mutation in the intracellular part of the calcium receptor (CaR) gene.
|
12161540 |
2002 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The cells were incubated with Raji cells and the LDH test was performed to detect the cytotoxic effect of CAR-T cells; the tumor volume and survival rate were measured to observe its inhibitory effect on B cell lymphoma in nude mice.
|
26195067 |
2015 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
These works confirmed that simultaneous use of cytokines, for example, rhIL-12, can increase the anti-tumor activity of CAR-T cells, especially for treatments of several types of solid tumors.
|
31237116 |
2019 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
High-Throughput Flow Cytometric Method for the Simultaneous Measurement of CAR-T Cell Characterization and Cytotoxicity against Solid Tumor Cell Lines.
|
29634393 |
2018 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Our results guide new therapeutic options for GD2.CAR-Ts in patients with neuroblastoma, and CAR-T development for a broad range of solid tumors.
|
30617136 |
2019 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy.
|
30999624 |
2019 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Here, we reviewed the solid tumor CAR-T clinical trials, emphasizing the studies with published results.
|
29433552 |
2018 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This review summarizes difference of CAR T applications in solid and blood cancers.
|
28272967 |
2017 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This study offers a reference for future research regarding the application in solid and hematologic malignancies, side effects and relapse, and even the production processes of CAR T cells.
|
30621018 |
2019 |
|
Hematologic Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CAR-T therapy has shown great success treating blood cancers, but drawbacks include high manufacturing costs and potentially fatal toxicities such as cytokine release syndrome.
|
30075127 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Management of cytokine release syndrome related to CAR-T cell therapy.
|
31571160 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Meanwhile, CAR-T therapy-related toxicities, including cytokine release syndrome (CRS) and neurological toxicities, are drawing researchers' attention.
|
31055613 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES) are common, predictable and potentially lethal side effects.
|
30072559 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) is the most significant complication associated with CAR T cell therapy, and it is critical to have a reproducible and easy method to grade CRS after CAR T cell infusions.
|
29499750 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, CAR-T therapy-related severe cytokine release syndrome and neurological toxicity limit its clinical application in R/R DLBCL patients with high tumor burden.
|
31219975 |
2020 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) is a common and potentially fatal complication of CAR-T cell therapy.
|
29443792 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Correction to: Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
|
29895316 |
2018 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most common severe adverse events in the CAR-T group were cytokine release syndrome, neurotoxicity and infection compared with cytopenia, gastrointestinal toxicity and infection in the ASCT group.
|
31335321 |
2019 |
|
Cytokine Release Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cytokine release syndrome (CRS) and CAR-T-associated encephalopathy syndrome (neurotoxicity) are the most common adverse effects associated with CAR-T therapy.
|
30560413 |
2019 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the cost-effectiveness of CAR-T therapy among pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).
|
30551196 |
2018 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.
|
30518999 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line.
|
28960810 |
2018 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chimeric antigen receptor T (CAR-T) cell therapies have been approved for use in relapsed or refractory leukemia and lymphoma based on promising efficacy in clinical trials.
|
30500439 |
2019 |
|
Adult Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma.
|
30841880 |
2019 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this report, we performed a meta-analysis to evaluate the efficacy and side effects of CAR-T on refractory and/or relapsed B-cell malignancies, including leukemia and lymphoma.
|
28762313 |
2019 |